ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
Healthcare
$10.90 +1.40%
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
52W Low $16.10High $33.62
Volume 2.70M
Average 0.50M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$177.53M
FY 2025 · Annual
Net Income
-$166.31M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| 1.28M | 33.49M | 31.96M | 31.47M | 38.46M | |
| 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
AVBP Earnings Waterfall · TTM
NASDAQ:AVBP · Revenue to Net Income
Key Ratios
EPS$-3.53
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$145.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.53, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 8-K | Current report | Oct 26, 2026 |
How much revenue does AVBP generate?
ArriVent BioPharma, Inc. Common Stock (AVBP) reported $0.00 of revenue in fiscal 2025.
Is AVBP profitable?
ArriVent BioPharma, Inc. Common Stock (AVBP) reported -$166.31M of net income.
Continue the stock analysis
Jump to another research area for this company.